1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > AB Science SA - Product Pipeline Review - 2015

AB Science SA - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 38 pages

AB Science SA - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘AB Science SA - Product Pipeline Review - 2015’, provides an overview of the AB Science SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AB Science SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AB Science SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AB Science SA’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the AB Science SA’s pipeline products

Reasons to buy

- Evaluate AB Science SA’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AB Science SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AB Science SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AB Science SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AB Science SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AB Science SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

AB Science SA - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
AB Science SA Snapshot 5
AB Science SA Overview 5
Key Information 5
Key Facts 5
AB Science SA - Research and Development Overview 6
Key Therapeutic Areas 6
AB Science SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
AB Science SA - Pipeline Products Glance 11
AB Science SA - Late Stage Pipeline Products 11
Filing rejected/Withdrawn Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
AB Science SA - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
AB Science SA - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
AB Science SA - Drug Profiles 16
masitinib 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
AB-8779 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
AB Science SA - Pipeline Analysis 23
AB Science SA - Pipeline Products by Target 23
AB Science SA - Pipeline Products by Route of Administration 24
AB Science SA - Pipeline Products by Molecule Type 25
AB Science SA - Pipeline Products by Mechanism of Action 26
AB Science SA - Recent Pipeline Updates 27
AB Science SA - Dormant Projects 34
AB Science SA - Discontinued Pipeline Products 35
Discontinued Pipeline Product Profiles 35
masitinib 35
AB Science SA - Locations And Subsidiaries 36
Head Office 36
Other Locations and Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
AB Science SA, Key Information 5
AB Science SA, Key Facts 5
AB Science SA - Pipeline by Indication, 2015 7
AB Science SA - Pipeline by Stage of Development, 2015 9
AB Science SA - Monotherapy Products in Pipeline, 2015 10
AB Science SA - Filing rejected/Withdrawn, 2015 11
AB Science SA - Phase III, 2015 12
AB Science SA - Phase II, 2015 13
AB Science SA - Preclinical, 2015 14
AB Science SA - Discovery, 2015 15
AB Science SA - Pipeline by Target, 2015 23
AB Science SA - Pipeline by Route of Administration, 2015 24
AB Science SA - Pipeline by Molecule Type, 2015 25
AB Science SA - Pipeline Products by Mechanism of Action, 2015 26
AB Science SA - Recent Pipeline Updates, 2015 27
AB Science SA - Dormant Developmental Projects,2015 34
AB Science SA - Discontinued Pipeline Products, 2015 35
AB Science SA, Other Locations 36

List of Figures
AB Science SA - Pipeline by Top 10 Indication, 2015 7
AB Science SA - Pipeline by Stage of Development, 2015 9
AB Science SA - Monotherapy Products in Pipeline, 2015 10
AB Science SA - Pipeline by Top 10 Target, 2015 23
AB Science SA - Pipeline by Top 10 Route of Administration, 2015 24
AB Science SA - Pipeline by Top 10 Molecule Type, 2015 25
AB Science SA - Pipeline Products by Top 10 Mechanism of Action, 2015 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histamine H4 Recepto ...

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.